Clinical trials
Lupus Erythematosus clinical trials
Below are recruiting lupus erythematosus clinical trials, each written for real people, not researchers. We’re tracking 260 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06449794Recruiting
Brain and behavior issues in children with Lupus
This study looks at brain and behavior problems in children with Lupus (SLE). It aims to understand how often these problems happen and what they look like, so doctors can better care for children with SLE.
SohagAges 1 year+ - NCT06133972RecruitingPhase 3
Long-term safety of ianalumab for lupus (extension study)
This extension study tests the long-term safety of ianalumab for people with systemic lupus erythematosus. If you completed a prior SIRIUS-SLE study and your doctor thinks you'd benefit, you may continue treatment for up to 60 more weeks.
Anniston, AlabamaAges 12–100 - NCT00512694Recruiting
Duke lupus registry for people with lupus
This trial is a registry that follows people with lupus to help Duke researchers learn about the disease and care. You may be able to join if you’re seen by a Duke rheumatologist and can come to follow-up visits.
Durham, North CarolinaAges 18 years+ - NCT06917742RecruitingPhase 1
Study of CPTX2309 for rheumatoid arthritis and lupus
This trial tests an investigational drug called CPTX2309, given intravenously, for people with moderate to severe rheumatoid arthritis or systemic lupus erythematosus. It aims to see if the drug is safe and effective.
Herston, QueenslandAges 18–65 - NCT06365359Recruiting
Lupus and pesticide exposure in Martinique
This study looks at how exposure to a pesticide called chlordecone might affect people with lupus in Martinique. Researchers want to understand if there is a link between the chemical and lupus symptoms or kidney problems.
Fort-de-FranceAges 18 years+ - NCT07607964RecruitingPhase 1
ABBV-519 Study for Lupus or Rheumatoid Arthritis
This early-stage trial tests a new drug called ABBV-519 given as infusions or injections to treat systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) in adults whose disease hasn't responded well to other treatments. Researchers will measure how safe the drug is, how it moves through your body, and whether it helps reduce symptoms.
Anniston, AlabamaAges 18–75 - NCT00198068Recruiting
Study pregnancy outcomes in lupus and antiphospholipid syndrome
This study looks for factors that may predict how pregnancy turns out in people with lupus (SLE) and/or antiphospholipid syndrome (APS). It may help doctors better understand what to monitor in early pregnancy to support healthier outcomes.
Chicago, IllinoisAges 18–45 - NCT07440537RecruitingPhase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)
This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.
Hefei, AnhuiAges 18–75 - NCT07276958RecruitingPhase 1
Study of LY4298445 for Lupus and Rheumatoid Arthritis
This trial tests a new drug called LY4298445 in healthy people and those with lupus or rheumatoid arthritis. It aims to see if the drug is safe and how the body processes it.
BrisbaneAges 18–55 - NCT06804057Recruiting
SLE drug safety registry for adults with lupus
This registry tracks the safety and effectiveness of lupus treatments over time. If you have SLE and are starting a new treatment or were recently diagnosed, joining helps doctors learn which medicines work best.
Waltham, MassachusettsAges 18 years+ - NCT06822881RecruitingPhase 1
Cell therapy for lupus and scleroderma
This trial tests a new cell therapy (CT1190B) for people with moderate to severe lupus or systemic sclerosis that has not responded to standard treatments. The therapy aims to calm the overactive immune system causing these autoimmune diseases.
Beijing, Beijing MunicipalityAges 18–60 - NCT06676631RecruitingPhase 1
NK cells plus rituximab for active lupus
This study tests whether combining immune cells (NK cells) with rituximab can help people with hard-to-treat lupus or lupus-related kidney disease. It is for patients whose lupus is still active despite standard treatments.
Guangzhou, GuangdomgAges 18–65 - NCT07491900RecruitingPhase 1
Study of HB2198 for lupus with moderate to severe symptoms
This trial tests a new drug called HB2198 to see if it can help people with moderate to severe lupus. It may be an option for those whose current treatments haven't worked well enough.
BrisbaneAges 18–65 - NCT06916806RecruitingPhase 1
Study of AZD5492 for lupus, myositis, or rheumatoid arthritis
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
Anniston, AlabamaAges 18–70 - NCT07041801RecruitingPhase 1/Phase 2
Stem cell therapy for lupus patients
This trial tests whether a type of stem cell from umbilical cords can help people with systemic lupus erythematosus (an autoimmune disease). It aims to find a new way to reduce lupus symptoms and improve quality of life.
Shenzhen, GuangdongAges 18–65 - NCT07175285Recruiting
Study for lupus patients not helped by steroids and 2 immunosuppressants
This trial tests a new treatment for people with active lupus who haven't responded well to steroids and at least two other immune-suppressing drugs, including a biologic. It aims to find a better option for controlling lupus symptoms.
Mesa, ArizonaAges 16 years+ - NCT07331272RecruitingPhase 1
CAR T-cells for lupus and myositis
This trial tests a new treatment using your own immune cells (CAR T-cells) targeted at a marker called CD19. It is for people whose lupus or myositis has not been controlled by other treatments.
Bengbu, AnhuiAges 18–70 - NCT06551389Recruiting
Lupus follow-up study at Brest Hospital
This study follows people with systemic lupus erythematosus (an autoimmune disease) who are seen in a special clinic. It aims to track their health over time.
BrestAges 18 years+ - NCT06977724RecruitingPhase 1
Testing a new drug for lupus, sjogren's, and rheumatoid arthritis
This study tests an experimental medicine given by IV infusion to see if it is safe and helps reduce symptoms of lupus, sjogren's disease, or rheumatoid arthritis. It is an early-phase trial, so the main goals are checking side effects and how the drug behaves in the body, but it will also look at how well it works.
Avon Park, FloridaAges 18–75 - NCT06576271RecruitingPhase 1
Testing a new drug for lupus and related lung disease
This study tests an experimental drug called GSK4527363. It is first being given to healthy volunteers to check safety, then to people with lupus (SLE) and people with connective tissue disease-related lung disease (CTD-ILD). The goal is to see if the drug is safe and how the body processes it.
Scottsdale, ArizonaAges 18–65 - NCT06718283Recruiting
A study of blood tests in young people with lupus
This study looks at blood test results in children and teenagers with lupus to see if they relate to how active the disease is or if it has caused long-term damage. It may help doctors better understand the disease.
SohagAges Up to 18 years - NCT06839976RecruitingPhase 1/Phase 2
CART19 cell therapy for lupus in young people
This trial tests whether a special type of immune cell, called CART19, can help young people with active lupus that hasn't gotten better with standard treatments. If you join, doctors will take some of your blood cells, modify them to attack lupus-causing cells, and then give them back to you.
Philadelphia, PennsylvaniaAges 12–29 - NCT07719140RecruitingPhase 4
Lower steroid dose study for children with lupus nephritis
This trial tests whether a lower starting dose of steroids can control kidney inflammation in children with lupus nephritis. It aims to reduce side effects while still treating the disease effectively.
Beijing, Beijing MunicipalityAges 6–18 - NCT07215754Recruiting
Real-world study of anifrolumab for active lupus
This study tracks how well anifrolumab works and how safe it is for people with active lupus. It's a real-world look at the drug's effects, so no additional treatments or tests are required beyond what your doctor already prescribes.
PisaAges 18 years+
Hear when a new Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for lupus erythematosus?
- Yes. Clin2 currently lists 260 recruiting lupus erythematosus studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a lupus erythematosus trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a lupus erythematosus trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.